Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ARS Pharmaceuticals, Inc. (SBTX)
|
Add to portfolio |
|
|
|
| Price: |
$6.03
| | Metrics |
| OS: |
95.6
|
M
| |
|
|
| Market cap: |
$576
|
M
| |
|
|
|
Net cash:
|
$252
|
M
| |
$2.64
|
per share
|
|
EV:
|
$324
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($78.6)
|
M
| |
|
|
| EPS |
($0.52)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 1.3 | 18.4 | 5.5 | 20.3 | 24.6 | 21.5 | 14.8 |
| Revenue growth | -76.1% | -9.4% | -77.6% | | 14.3% | 45.3% | |
| Cost of goods sold | 0.0 | 36.8 | 0.0 | 25.0 | 32.9 | 24.1 | 18.3 |
| Gross profit | 1.3 | -18.5 | 5.5 | -4.7 | -8.3 | -2.6 | -3.5 |
| Gross margin | 100.0% | -100.4% | 100.0% | -23.1% | -33.9% | -11.9% | -23.8% |
| Research and development | 18.4 | | 20.3 | | | | |
| General and administrative | 18.5 | 18.5 | 4.7 | 4.7 | 8.3 | 2.6 | 3.5 |
| EBIT | -35.5 | -35.5 | -19.5 | -19.5 | -32.9 | -24.1 | -18.3 |
| EBIT margin | -2698.8% | -193.3% | -353.3% | -96.0% | -133.9% | -111.9% | -123.8% |
| Pre-tax income | -34.7 | -34.7 | -20.2 | -20.2 | 0.0 | 0.0 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | | | |
| Net income | -34.7 | -34.7 | -20.2 | -20.2 | 0.0 | 0.0 | 0.0 |
| Net margin | -2635.4% | -188.7% | -367.7% | -99.9% | 0.0% | 0.0% | 0.0% |
| |
| Diluted EPS | ($0.87) | ($0.87) | ($0.70) | ($0.70) | $0.00 | $0.00 | $0.00 |
| Shares outstanding (diluted) | 40.0 | 40.0 | 28.9 | 28.9 | 2,907.5 | 660.9 | 603.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|